← Back to headlines
Merck Strikes Nearly $6 Billion Deal to Acquire Cancer Biotech Terns
Pharmaceutical giant Merck has reached an agreement for a deal valued at nearly $6 billion to acquire Terns, a biotechnology company focused on cancer research.
26 Mar, 08:02 — 26 Mar, 08:02
Sources
Showing 1 of 1 sources
